Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CLLM1-Protocol of the German CLL-Study Group (GCLLSG) A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) as Maintenance Therapy for High-risk Patients With Chronic Lymphocytic Leukemia Following First-line Therapy
Brief Summary: CLLM1 is a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study that compares the efficacy and safety of oral lenalidomide maintenance therapy to that of placebo maintenance therapy in high-risk subjects with Chronic Lymphocytic Leukemia (CLL) who have achieved at least a partial response (PR) and either:

* MRD levels of ≥ 10-2 or
* MRD levels of ≥ 10-4 - \< 10-2 combined with at least one of the following factors:

  * an unmutated IGHV-status
  * 17p-deletion or
  * TP53 mutation after first line therapy with FCR, FR, BR or FC (in case of of contraindications to receive Rituximab).


Options:
A: Arm Label: Arm A (ibrutinib, rituximab); Type: EXPERIMENTAL; Interventions: Drug: Ibrutinib, Other: Laboratory Biomarker Analysis, Other: Pharmacogenomic Study, Other: Quality-of-Life Assessment, Biological: Rituximab | Arm Label: Arm B (rituximab, fludarabine phosphate, cyclophosphamide); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Fludarabine Phosphate, Other: Laboratory Biomarker Analysis, Other: Pharmacogenomic Study, Other: Quality-of-Life Assessment, Biological: Rituximab | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: DRUG; Name: Fludarabine Phosphate; Assigned to Arm(s): Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Arm A (ibrutinib, rituximab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm A (ibrutinib, rituximab), Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: OTHER; Name: Pharmacogenomic Study; Assigned to Arm(s): Arm A (ibrutinib, rituximab), Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm A (ibrutinib, rituximab), Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): Arm A (ibrutinib, rituximab), Arm B (rituximab, fludarabine phosphate, cyclophosphamide)
B: Arm Label: Arm A - Obinutuzumab in Combination with Chlorambucil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Obinutuzumab, Drug: Chlorambucil | Arm Label: Arm B - Acalabrutinib in Combination with Obinutuzumab; Type: EXPERIMENTAL; Interventions: Drug: Acalabrutinib, Drug: Obinutuzumab | Arm Label: Arm C - Acalabrutinib Monotherapy; Type: EXPERIMENTAL; Interventions: Drug: Acalabrutinib | Intervention Type: DRUG; Name: Acalabrutinib; Assigned to Arm(s): Arm B - Acalabrutinib in Combination with Obinutuzumab, Arm C - Acalabrutinib Monotherapy | Intervention Type: DRUG; Name: Obinutuzumab; Assigned to Arm(s): Arm A - Obinutuzumab in Combination with Chlorambucil, Arm B - Acalabrutinib in Combination with Obinutuzumab | Intervention Type: DRUG; Name: Chlorambucil; Assigned to Arm(s): Arm A - Obinutuzumab in Combination with Chlorambucil
C: Arm Label: Lenalidomide; Type: EXPERIMENTAL; Interventions: Drug: lenalidomide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: lenalidomide; Assigned to Arm(s): Lenalidomide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Treatment Arm; Type: EXPERIMENTAL; Interventions: Drug: Lenalidomide, Drug: Fludarabine, Biological: Rituximab | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): Treatment Arm | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): Treatment Arm | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): Treatment Arm

Answer: C